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INTRODUCTION
●  Atypical haemolytic uraemic syndrome (aHUS) is a rare, genetic, 
life-threatening disease predominantly caused by chronic, 
uncontrolled complement activation that leads to thrombotic 
microangiopathy (TMA) and renal and other end-organ damage.
●  Historically, disease outcomes have been dire – over 50% of 
patients with aHUS die, have required dialysis, or have developed 
permanent kidney damage within 1 year, despite the use of 
plasma exchange or plasma infusion.1
●  Eculizumab, a humanised monoclonal antibody that inhibits 
alternative pathway activation by blocking the generation of 
C5b-9 (membrane attack complex),2 has been shown to be 
effective in treating patients with aHUS.3-5
●  Patient registries can lead to improved knowledge of the natural 
history of a disease and, dependent on the data collected, can 
be analysed to evaluate the effectiveness of clinical therapies, 
monitor drug safety and measure the quality of care in a real life 
setting.6,7
●  The global aHUS Registry was initiated in April 2012 to:
–  Record information on the natural history of aHUS patients, 
irrespective of treatment. 
–  Prospectively collect safety and effectiveness data on patients 
treated with eculizumab.
–  Fulfil Alexion’s post-marketing regulatory requirements by 
providing long-term follow-up on the aHUS indication for 
eculizumab.8
OBJECTIVE
●  To report baseline paediatric and adult demographics, genotype 
and phenotype from the global aHUS Registry specifically for 
patients enrolled in the UK.
METHODS
Inclusion / exclusion criteria
●  All patients who have been clinically diagnosed with aHUS are 
eligible for enrolment:
–  With or without identified complement abnormalities or anti-
complement factor H antibody (if tested).
●  Patients with cases of Shiga toxin Escherichia coli-positive HUS, 
or ADAMTS13 activity <5% are excluded.
Data collection
Data that are collected at enrolment and every 6 months thereafter 
include:
●  Demographics, medical and disease history.
●  Symptomology and laboratory results.
●  TMA complications and safety of eculizumab treatment and other 
aHUS management strategies.
●  Clinical and patient reported outcomes.
Data analysis
●  Baseline is defined as date of enrolment or immediately before 
eculizumab treatment, whichever occurred earlier.
●  Patients with all of the following data were included:
–  Date of birth, gender, Registry enrolment date.
–  Knowledge of treatment with eculizumab or no previous 
eculizumab treatment. 
–  For eculizumab-treated patients, date of first  
eculizumab dose.
●  Patients were stratified by age at enrolment into the Registry.
Registry support
●  The Registry is supported by Alexion Pharmaceuticals, Inc., with 
governance by an independent scientific advisory board and 
national coordinators representing each participating country.
RESULTS
Baseline characteristics
●  Worldwide, as of 30 November 2015, 964 patients were enrolled 
from 18 countries (Figure 1). 
Figure 1. Patients enrolled per million by country population
●  Enrolment per million inhabitants was 1.56 in UK compared with 
a median of 1.28 (range, 0.18–4.25) for the 18 countries.
●  To date, 101 patients have enrolled in 19 centres across the UK 
(Figure 2).
Figure 2. Patients enrolled in UK centres
●  Demographic characteristics for the overall global Registry and 
UK patients were generally similar (Table 1).
Table 1. Demographic characteristics
Global (N=964) UK (N=99)
Paediatric
(n=367)
Adult
(n=597)
Paediatric
(n=45)
Adult
(n=54)
Gender, n (%)
Male
Female
 
197 (54)
170 (46)
 
227 (38)
370 (62)
 
23 (51)
22 (49)
 
20 (37)
34 (63)
Age at enrolment,
years, median (range)
8.0
(0.0–17.9)
39.9
(18.0–90.6)
7.4
(0.6–17.9)
39.5
(19.2–80.8)
Age at initial aHUS
symptoms, years median 
(range)
 
3.41
(0.0–17.3)
 
32.62
(0.1–90.6)
 
2.54
(0.3–16.9)
 
28.25
(0.3–74.7)
Age (years) at initial
symptoms of
aHUS, n (%)
<2 
≥2 to <5 
≥5 to <12 
≥12 to <18 
≥18 
 
 
 
137 (38)
82 (23)
109 (30)
30 (8)
–
 
 
 
20 (4)
13 (2)
17 (3)
18 (3)
484 (81)
 
 
 
19 (44)
10 (23)
10 (23)
4 (9)
–
 
 
 
2 (4)
2 (4)
0 (0)
1 (2)
46 (85)
Family history of
aHUS, n (%)
 
56 (15)
 
83 (14)
 
6 (13)
 
8 (15)
●  Just over one third (37%) of the overall Registry population were 
aged <18 years compared to 43% in the UK registry at initial 
symptoms. 
●  Across the two paediatric and adult populations, gender and age 
at enrolment were similar.
●  A family history of aHUS was similar between both populations.
Eculizumab treatment
●  Approximately two thirds of global Registry patients, compared 
with half of patients enrolled in the UK, have received 
eculizumab treatment (Table 2).
●  Within each population, the proportion of paediatric and adult 
patients ever receiving eculizumab treatment were similar.
●  The proportion of adults receiving eculizumab prior to enrolment 
is lower in the UK (60%) compared with the overall global 
population (84.7%), though time on treatment was similar. 
●  Initiation of eculizumab treatment after diagnosis of aHUS 
appeared to be quicker in UK paediatric patients (median time 
0.02 years vs 0.06 years) but slower in UK adult patients (median 
time 7.14 years vs 0.06 years), compared to the overall population.
Table 2. Eculizumab treatment
Global UK
Paediatric
(n=367)
Adult
(n=597)
Paediatric
(n=45)
Adult
(n=54)
Received
eculizumab, n (%)
Of whom received 
eculizumab prior to
enrolment, n (%)
 
230 (67) 
 
 
205 (89)
 
352 (64) 
 
 
298 (85)
 
21 (50) 
 
 
19 (90)
 
25 (51) 
 
 
15 (60)
Time from aHUS
diagnosis to
initiation of
eculizumab, years, 
median (range)
 
 
 
0.06
(0–17.0)
 
 
 
0.06
(0–36.3)
 
 
 
0.02
(0–5.5)
 
 
 
7.14
(0–28.4)
Time on eculizumab,
years, median (range)
1.44
(0–5.7)
0.89
(0–6.9)
2.04
(0.1–4.6)
0.83
(0–3.6)
Clinical characteristics at baseline and prior 
management in the UK population
●  Within the enrolled UK aHUS patient population, the proportion 
of paediatric and adult patients receiving PE/PI prior to baseline 
were similar, regardless of eculizumab treatment.
●  Paediatric patients who went on to be treated with eculizumab 
tended to have had less prior dialysis and transplants, while the 
opposite was true for the adult population (Table 3).
●  Organ manifestations were rarely reported in the patient 
group that had never been treated with eculizumab while the 
proportion of extrarenal manifestations ranged from 12-28% in 
adults and 20-50% in paediatric patients that were subsequently 
treated with eculizumab. 
Table 3. Clinical characteristics at baseline of UK 
aHUS patients who did or did not subsequently 
receive eculizumab treatment.
Ever treated with 
eculizumab
Never treated with  
eculizumab
Paediatric
(n=20)
Adult
(n=25)
Paediatric
(n=21)
Adult
(n=24)
Prior kidney
transplantation, n (%)
 
1 (5)
 
8 (32)
 
5 (24)
 
5 (21)
Prior dialysis, n (%) 7 (35) 20 (80) 13 (62) 14 (58)
Prior PE/PI, n (%) 8 (40) 15 (60) 9 (43) 19 (79)
Symptoms experienced 6 months prior to baseline
Renal, n (%) 18 (90) 16 (64) 0 (0) 1 (4)
GI, n (%) 10 (50) 5 (20) 0 (0) 1 (4)
CV, n (%) 7 (35) 7 (28) 1 (5) 0 (0)
Pulmonary, n (%) 5 (25) 3 (12) 0 (0) 1 (4)
CNS, n (%) 4 (20) 6 (24) 0 (0) 0 (0)
Genetic analysis and extrarenal manifestations
●  Within the global Registry, complement abnormality was identified 
in 46% of patients tested (Table 4).
●  In patients from the global Registry with an identified complement 
abnormality, extrarenal manifestations were common (44–75%), 
figure 3.
●  Extrarenal manifestations appear to be most common in patients 
with C3 mutations and least common in patients with CFI mutations.
Table 4. Complement abnormalities identified in patients 
enrolled in the global aHUS Registry
Paediatric n (%)a Adult n (%)a
CFH 74 (32) 87 (35)
MCP 39 (20) 22 (11)
C3 21 (13) 21 (13)
CFI 8 (4) 26 (12)
CFB 3 (2) 2 (2)
Anti-CFH Ab 47 (24) 39 (19)
Data presented from n=851. aPercentage of patients tested for that particular abnormality. 
Figure 3. Extrarenal manifestations associated with 
complement abnormalities in patients with baseline data 
≤6 months from disease onset (overall global population).
CONCLUSION
●  This is the first comparison of UK and global baseline data of 
the aHUS Registry and shows that characteristics are generally 
comparable.
●  A significant proportion of UK patients had received supportive 
care or eculizumab prior to study enrolment.
●  Initiation of eculizumab treatment after aHUS diagnosis is 
slower for UK adult patients.
●  A significant proportion of patients showed extrarenal 
manifestations.
●  Patients subsequently treated with eculizumab had more extra-
renal manifestations, suggesting that a more severe disease 
presentation with multiple organ system complications increases 
the likelihood for these patients to be treated with eculizumab.
●  Emerging data aim to link genetic mutations to outcomes or 
treatment strategies.
●  By maintaining quality assurance of data collection, data from 
the global aHUS Registry will improve understanding of the 
natural history of aHUS and may help optimise patient care 
while also allowing analysis of country- or region-specific data.
●  Enhancing enrolment in the UK will allow for more detailed 
analyses, including linking genetic mutations with extrarenal 
manifestations, to occur at the local level.  
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